Branch­ing out from di­a­betes? No­vo Nordisk shells out the big bucks for Prothena's AT­TR amy­loi­do­sis pipeline

Os­ten­si­bly look­ing to branch out from its di­a­betes fran­chis­es, No­vo Nordisk is mak­ing a ma­jor play in­to the amy­loid space — and pay­ing a pret­ty pen­ny to do so.

The Dan­ish phar­ma com­pa­ny is grab­bing a Prothena an­ti­body and wider pro­gram in AT­TR amy­loi­do­sis for $100 mil­lion up­front, the com­pa­nies an­nounced Mon­day morn­ing. Prothena’s can­di­date in ques­tion is the PRX004 com­pound, a mon­o­clon­al an­ti­body de­signed to de­plete amy­loid de­posits in hered­i­tary and wild type AT­TR amy­loi­do­sis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER